Vertex picks cystic fibrosis triple combos for Phase III trials

(Reuters) - Vertex Pharmaceuticals said on Wednesday it selected two next-generation cystic fibrosis drugs to advance into late-stage testing of triple-combination therapies that could eventually treat up to 90 percent of patients with the life-shortening lung disease.

Source: Reuters: Health - January 31, 2018 Category: Consumer Health News Tags: healthNews Source Type: news